title: Towards dissecting the pathogenesis of retinoid-induced hair loss: all-trans retinoic acid induces premature hair follicle regression (catagen) by upregulation of transforming growth factor-beta2 in the dermal papilla.
abstract: Diffuse hair loss ranks among the most frequent and psychologically most distressing adverse effects of systemic therapy with retinoids, which severely limits their therapeutic use even where clinically desired. Since the underlying mechanisms of retinoid-induced effluvium are as yet unknown, we have investigated the influence of the prototypic retinoid all-trans retinoic acid (ATRA, tretinoin) on the growth of human scalp hair follicles (HF) in culture. HF in the anagen VI stage of the hair cycle were cultured in the presence of 10(-8) or 10(-10) M ATRA. Compared with controls, hair shaft elongation declined significantly already after 2 d in the ATRA-treated group, and approximately 80% of the ATRA-treated HF had prematurely entered catagen-like stage at day 6, compared with 30% in the control group. This corresponded to an upregulation of apoptotic and a downregulation of Ki67-positive cells in ATRA-treated HF. Since transforming growth factor (TGF)-beta has been implicated as a key inducer of catagen, we next studied whether ATRA treatment had any effect on follicular expression. TGF-beta2 immunoreactivity was detected in the outer root sheath of anagen VI scalp HF. In catagen follicles, TGF-beta2 was also expressed in the regressing epithelial strand. After 4 d of ATRA treatment, TGF-beta2 was significantly upregulated in anagen HF in the dermal papilla (DP) and the dermal sheath, 7, and TGF-beta neutralizing antibody partially abrogated at RA induced hair growth inhibition. Real-time PCR confirmed a significant upregulation of TGF-beta2 transcripts in ATRA-treated hair bulbs. This study is the first to provide direct evidence that ATRA can indeed induce a catagen-like stage in human HF and suggests that this occurs, at least in part, via upregulation of TGF-beta2 in the DP. Therefore, topical TGF-beta2/TGF-beta receptor II antagonists deserve to be explored for the prevention and management of retinoid-induced hair loss.
authors.affiliation: Department of Dermatology, University Hospital Hamburg-Eppendorf, University of Hamburg, Hamburg, Germany.
authors.forename: Kerstin
authors.initials: K
authors.lastname: Foitzik
authors.forename: Tanja
authors.initials: T
authors.lastname: Spexard
authors.forename: Motonobu
authors.initials: M
authors.lastname: Nakamura
authors.forename: Ursula
authors.initials: U
authors.lastname: Halsner
authors.forename: Ralf
authors.initials: R
authors.lastname: Paus
mesh_terms: D000906:Antibodies / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D020405:Dermis / Q000187:drug effects / Q000378:metabolism*; D006197:Hair / Q000187:drug effects / Q000254:growth & development; D018859:Hair Follicle / Q000187:drug effects*; D006801:Humans; D007039:Hypotrichosis / Q000139:chemically induced*; D015603:Keratinocytes / Q000166:cytology / Q000502:physiology; D012176:Retinoids / Q000009:adverse effects*; D016212:Transforming Growth Factor beta / Q000276:immunology / Q000378:metabolism*; D053781:Transforming Growth Factor beta2; D014212:Tretinoin / Q000494:pharmacology*; D015854:Up-Regulation
chemical_list: D000906:Antibodies; D012176:Retinoids; C509041:TGFB2 protein, human; D016212:Transforming Growth Factor beta; D053781:Transforming Growth Factor beta2; D014212:Tretinoin